FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130957260> ?p ?o ?g. }

• W2130957260 endingPage "2816" @default.
• W2130957260 startingPage "2809" @default.
• W2130957260 abstract "Many clinical trials of oncology drugs now include at least a consideration of pharmacogenomics, the study of germline or acquired genetic factors governing a drug's response and toxicity. Besides the potential benefit to patients from the consideration of personalized pharmacogenomic information when making treatment decisions, the incentive is clear for oncology drug developers to incorporate pharmacogenomic factors in the drug development process, because pharmacogenomic biomarkers may allow predictive characterization of subpopulations within a disease that may particularly respond or may allow preidentification of patients at highest risk for adverse events. There is, however, a lack of agreement in actual practice about at what point in the oncology clinical drug development process pharmacogenomic studies should be incorporated. In this article, we examine the recent growth of pharmacogenomics in oncology clinical trials, especially in early-phase studies, and examine several critical questions facing the incorporation of pharmacogenomics in early oncologic drug development. We show that phase II clinical trials, in particular, have a favorable track record for showing positive pharmacogenomic signals, worthy of additional follow-up and validation, and that the phase II setting holds significant promise for potentially accelerating and informing future phase III trials. We conclude that phase II trials offer an ideal “sweet spot” for routine incorporation of pharmacogenomic questions in oncology drug development. Clin Cancer Res; 18(10); 2809–16. ©2012 AACR." @default.
• W2130957260 created "2016-06-24" @default.
• W2130957260 creator A5018398274 @default.
• W2130957260 creator A5088131964 @default.
• W2130957260 date "2012-03-16" @default.
• W2130957260 modified "2023-10-14" @default.
• W2130957260 title "Pharmacogenomics in Early-Phase Oncology Clinical Trials: Is There a Sweet Spot in Phase II?" @default.
• W2130957260 cites W1551600243 @default.
• W2130957260 cites W1935448348 @default.
• W2130957260 cites W1980987539 @default.
• W2130957260 cites W1993213958 @default.
• W2130957260 cites W1998641738 @default.
• W2130957260 cites W2012711528 @default.
• W2130957260 cites W2041649054 @default.
• W2130957260 cites W2048585188 @default.
• W2130957260 cites W2049940728 @default.
• W2130957260 cites W2068584083 @default.
• W2130957260 cites W2076909095 @default.
• W2130957260 cites W2079777659 @default.
• W2130957260 cites W2083490815 @default.
• W2130957260 cites W2083637030 @default.
• W2130957260 cites W2093922887 @default.
• W2130957260 cites W2102316672 @default.
• W2130957260 cites W2105099533 @default.
• W2130957260 cites W2105216346 @default.
• W2130957260 cites W2113818262 @default.
• W2130957260 cites W2131115715 @default.
• W2130957260 cites W2132756648 @default.
• W2130957260 cites W2134654916 @default.
• W2130957260 cites W2135192471 @default.
• W2130957260 cites W2136934667 @default.
• W2130957260 cites W2142572653 @default.
• W2130957260 cites W2145238269 @default.
• W2130957260 cites W2148121875 @default.
• W2130957260 cites W2156927517 @default.
• W2130957260 cites W2157800394 @default.
• W2130957260 cites W2158245822 @default.
• W2130957260 cites W2161630562 @default.
• W2130957260 cites W2164710835 @default.
• W2130957260 cites W2165460636 @default.
• W2130957260 cites W2168909179 @default.
• W2130957260 cites W2170566133 @default.
• W2130957260 cites W2297165308 @default.
• W2130957260 cites W2318605753 @default.
• W2130957260 doi "https://doi.org/10.1158/1078-0432.ccr-11-2445" @default.
• W2130957260 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3354016" @default.
• W2130957260 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22427349" @default.
• W2130957260 hasPublicationYear "2012" @default.
• W2130957260 type Work @default.
• W2130957260 sameAs 2130957260 @default.
• W2130957260 citedByCount "6" @default.
• W2130957260 countsByYear W21309572602013 @default.
• W2130957260 countsByYear W21309572602016 @default.
• W2130957260 countsByYear W21309572602017 @default.
• W2130957260 countsByYear W21309572602019 @default.
• W2130957260 crossrefType "journal-article" @default.
• W2130957260 hasAuthorship W2130957260A5018398274 @default.
• W2130957260 hasAuthorship W2130957260A5088131964 @default.
• W2130957260 hasBestOaLocation W21309572601 @default.
• W2130957260 hasConcept C121608353 @default.
• W2130957260 hasConcept C126322002 @default.
• W2130957260 hasConcept C143998085 @default.
• W2130957260 hasConcept C170734499 @default.
• W2130957260 hasConcept C177713679 @default.
• W2130957260 hasConcept C2780035454 @default.
• W2130957260 hasConcept C32220436 @default.
• W2130957260 hasConcept C535046627 @default.
• W2130957260 hasConcept C60644358 @default.
• W2130957260 hasConcept C64903051 @default.
• W2130957260 hasConcept C71924100 @default.
• W2130957260 hasConcept C86803240 @default.
• W2130957260 hasConcept C98274493 @default.
• W2130957260 hasConceptScore W2130957260C121608353 @default.
• W2130957260 hasConceptScore W2130957260C126322002 @default.
• W2130957260 hasConceptScore W2130957260C143998085 @default.
• W2130957260 hasConceptScore W2130957260C170734499 @default.
• W2130957260 hasConceptScore W2130957260C177713679 @default.
• W2130957260 hasConceptScore W2130957260C2780035454 @default.
• W2130957260 hasConceptScore W2130957260C32220436 @default.
• W2130957260 hasConceptScore W2130957260C535046627 @default.
• W2130957260 hasConceptScore W2130957260C60644358 @default.
• W2130957260 hasConceptScore W2130957260C64903051 @default.
• W2130957260 hasConceptScore W2130957260C71924100 @default.
• W2130957260 hasConceptScore W2130957260C86803240 @default.
• W2130957260 hasConceptScore W2130957260C98274493 @default.
• W2130957260 hasIssue "10" @default.
• W2130957260 hasLocation W21309572601 @default.
• W2130957260 hasLocation W21309572602 @default.
• W2130957260 hasLocation W21309572603 @default.
• W2130957260 hasLocation W21309572604 @default.
• W2130957260 hasOpenAccess W2130957260 @default.
• W2130957260 hasPrimaryLocation W21309572601 @default.
• W2130957260 hasRelatedWork W2000482836 @default.
• W2130957260 hasRelatedWork W2002327913 @default.
• W2130957260 hasRelatedWork W2111074312 @default.
• W2130957260 hasRelatedWork W2130957260 @default.
• W2130957260 hasRelatedWork W2165940983 @default.
• W2130957260 hasRelatedWork W2386081311 @default.

• next